Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Sep 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Negative Cash Flow RAPP has strong liquidity and low leverage, but declining cash, persistent losses, negative cash flow, and a premium-to-book valuation make it a high-risk investment.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Weak momentum ⢠Support test Support Level: $43.46â$43.62 Resistance Level: $45.77â$46.09 RAPP is bearish over the last month, down ~8% with lower highs/lows; watch $43.46â$43.62 support for a rebound, while a break below it targets $42.20â$42.44.
Sentiment & News
Key News Insights: ⢠Institutional buying ⢠RAP-219 focus ⢠Funding runway Rapport Therapeutics gains momentum from a 52-week high, rising institutional ownership and RAP-219 investor outreach, though regulatory and future funding risks remain.
AI Summary
RAPP is now a financed but binary clinical bet on RAP-219: positive October 2026 bipolar-mania data and Phase 3 epilepsy replication could justify substantial upside, while failure would undermine its premium $2B valuation and multi-indication thesis; investors should size positions around these catalysts and monitor accelerating cash burn.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |